Harbor Capital Advisors Inc. Buys 25,303 Shares of Vaxcyte, Inc. $PCVX

Key Points

• Harbor Capital Advisors Inc. increased its stake in Vaxcyte, Inc. by 32.8% during the second quarter, buying an additional 25,303 shares to own a total of 102,362 shares valued at approximately $3.3 million.
• Vaxcyte reported an earnings per share loss of ($1.22), missing market expectations, while analysts project a consensus target price of $106.25 for the stock.
• Most of Vaxcyte's stock, about 96.78%, is held by institutional investors, highlighting strong institutional interest in the company.

Harbor Capital Advisors Inc. grew its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 32.8% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 102,362 shares of the company's stock after buying an additional 25,303 shares during the period. Harbor Capital Advisors Inc. owned 0.08% of Vaxcyte worth $3,328,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Voya Investment Management LLC grew its stake in shares of Vaxcyte by 1.7% during the first quarter. Voya Investment Management LLC now owns 306,729 shares of the company's stock valued at $11,582,000 after purchasing an additional 5,169 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of Vaxcyte by 5.5% in the first quarter. Rhumbline Advisers now owns 181,230 shares of the company's stock valued at $6,843,000 after purchasing an additional 9,416 shares during the last quarter. Strs Ohio bought a new position in shares of Vaxcyte in the first quarter valued at approximately $627,000. Intech Investment Management LLC raised its stake in shares of Vaxcyte by 44.3% during the first quarter. Intech Investment Management LLC now owns 89,212 shares of the company's stock worth $3,369,000 after acquiring an additional 27,384 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Vaxcyte by 8.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,998 shares of the company's stock worth $19,409,000 after purchasing an additional 41,034 shares in the last quarter. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Vaxcyte Stock Down 2.6%

PCVX stock traded down $0.84 during mid-day trading on Friday, reaching $31.75. The company had a trading volume of 4,055,858 shares, compared to its average volume of 1,602,792. The stock has a market capitalization of $4.12 billion, a P/E ratio of -7.73 and a beta of 1.04. The stock's 50-day simple moving average is $32.84 and its two-hundred day simple moving average is $37.58. Vaxcyte, Inc. has a one year low of $27.66 and a one year high of $118.62.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.10). During the same quarter last year, the company earned ($1.10) earnings per share. On average, research analysts forecast that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently weighed in on PCVX shares. The Goldman Sachs Group began coverage on Vaxcyte in a research report on Friday, September 12th. They set a "neutral" rating and a $38.00 target price for the company. Cowen restated a "buy" rating on shares of Vaxcyte in a research note on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $106.25.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.